Spots Global Cancer Trial Database for R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Official Title: Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Study ID: NCT00005843

Conditions

Pancreatic Cancer

Interventions

tipifarnib

Study Description

Brief Summary: Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Detailed Description: OBJECTIVES: I. Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic cancer. II. Determine the response rate, time to progression, and 6 month survival rate of these patients with this treatment regimen. III. Assess the pharmacokinetics of this treatment regimen in this patient population. OUTLINE: This is a multicenter study. Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year.